Cost-effectiveness of Trastuzumab Deruxtecan for HER2-low Advanced Breast Cancer in the United States
Authors:
- 1 August 2023
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 45 (10) , 965-972
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1Clinical Cancer Research, 2016
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness AnalysesJAMA, 2016
- Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast CancerJournal of Clinical Oncology, 2016
- Markov Model and Cost-Effectiveness Analysis of Bevacizumab in HER2-Negative Metastatic Breast CancerAmerican Journal of Clinical Oncology, 2014
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY ThresholdNew England Journal of Medicine, 2014
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curvesBMC Medical Research Methodology, 2012
- A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancerBreast Cancer Research and Treatment, 2011
- Health state utilities for metastatic breast cancerBritish Journal of Cancer, 2006
- Incremental cost-effectiveness ratio and incremental net-health benefit: two sides of the same coinExpert Review of Pharmacoeconomics & Outcomes Research, 2001
- Net Health BenefitsMedical Decision Making, 1998